CDK12 is altered in 5.49% of prostate carcinoma patients with CDK12 Loss present in 0.03% of all prostate carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 18 clinical trials for prostate carcinoma, of which 15 are open and 3 are closed. Of the trials that contain CDK12 Loss and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (9 open), and 1 is phase 3 (1 open) [5].

Olaparib has evidence of efficacy in patients with CDK12 Loss in prostate carcinoma [5].

CDK12 is altered in 3.83% of malignant solid tumor patients with CDK12 Loss present in 0.02% of all malignant solid tumor patients [4].

CDK12 Loss is an inclusion criterion in 33 clinical trials for malignant solid tumor, of which 26 are open and 7 are closed. Of the trials that contain CDK12 Loss and malignant solid tumor as inclusion criteria, 14 are phase 1 (10 open), 7 are phase 1/phase 2 (4 open), and 12 are phase 2 (12 open) [5].

CDK12 is altered in 8.26% of breast carcinoma patients with CDK12 Loss present in 0.03% of all breast carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 21 clinical trials for breast carcinoma, of which 16 are open and 5 are closed. Of the trials that contain CDK12 Loss and breast carcinoma as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [5].

CDK12 is altered in 5.48% of prostate adenocarcinoma patients with CDK12 Loss present in 0.03% of all prostate adenocarcinoma patients [4].

CDK12 Loss is an inclusion criterion in 19 clinical trials for prostate adenocarcinoma, of which 17 are open and 2 are closed. Of the trials that contain CDK12 Loss and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 16 are phase 2 (14 open), and 2 are phase 3 (2 open) [5].

CDK12 is altered in 4.21% of ovarian carcinoma patients with CDK12 Loss present in 0.15% of all ovarian carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 18 clinical trials for ovarian carcinoma, of which 13 are open and 5 are closed. Of the trials that contain CDK12 Loss and ovarian carcinoma as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 7 are phase 2 (6 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

CDK12 is altered in 9.09% of primary peritoneal carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 9 clinical trials for primary peritoneal carcinoma, of which 6 are open and 3 are closed. Of the trials that contain CDK12 Loss and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

CDK12 is altered in 11.97% of adenocarcinoma of the gastroesophageal junction patients [4].

CDK12 Loss is an inclusion criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain CDK12 Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [5].

CDK12 is altered in 3.64% of fallopian tube carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 8 clinical trials for fallopian tube carcinoma, of which 5 are open and 3 are closed. Of the trials that contain CDK12 Loss and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), 1 is phase 3 (0 open), and 1 is phase 4 (1 open) [5].

CDK12 is altered in 2.45% of non-small cell lung carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 5 are open and 2 are closed. Of the trials that contain CDK12 Loss and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

CDK12 is altered in 4.34% of colorectal carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain CDK12 Loss and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

CDK12 is altered in 5.48% of gastric carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain CDK12 Loss and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

CDK12 is altered in 1.52% of pancreatic adenocarcinoma patients [4].

CDK12 Loss is an inclusion criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain CDK12 Loss and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

CDK12 is altered in 1.52% of pancreatic carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 5 clinical trials for pancreatic carcinoma, of which 4 are open and 1 is closed. Of the trials that contain CDK12 Loss and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 2 (3 open) [5].

CDK12 is altered in 0.85% of soft tissue sarcoma patients with CDK12 Loss present in 0.11% of all soft tissue sarcoma patients [4].

CDK12 Loss is an inclusion criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain CDK12 Loss and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

CDK12 is altered in 2.36% of cervical carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDK12 Loss and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

CDK12 is altered in 5.58% of endometrial carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CDK12 Loss and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

CDK12 is altered in 5.53% of gastric adenocarcinoma patients [4].

CDK12 Loss is an inclusion criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain CDK12 Loss and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [5].

CDK12 is altered in 3.15% of head and neck carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 4 clinical trials for head and neck carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDK12 Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

CDK12 is altered in 1.61% of small cell lung carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 4 clinical trials for small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDK12 Loss and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [5].

CDK12 is altered in 4.59% of high grade ovarian serous adenocarcinoma patients with CDK12 Loss present in 0.21% of all high grade ovarian serous adenocarcinoma patients [4].

CDK12 Loss is an inclusion criterion in 3 clinical trials for high grade ovarian serous adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDK12 Loss and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

CDK12 is altered in 4.04% of melanoma patients [4].

CDK12 Loss is an inclusion criterion in 3 clinical trials for melanoma, of which 2 are open and 1 is closed. Of the trials that contain CDK12 Loss and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

CDK12 is altered in 6.35% of urothelial carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CDK12 Loss and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

CDK12 is altered in 5.95% of bladder carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDK12 Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

CDK12 is altered in 6.16% of bladder urothelial carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 Loss and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK12 is altered in 0.44% of clear cell renal cell carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 Loss and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK12 is altered in 8.95% of esophageal adenocarcinoma patients [4].

CDK12 Loss is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 Loss and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

CDK12 is altered in 7.92% of esophageal carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 Loss and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

CDK12 is altered in 0.6% of gastrointestinal stromal tumor patients [4].

CDK12 Loss is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain CDK12 Loss and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

CDK12 is altered in 2.53% of head and neck squamous cell carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDK12 Loss and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

CDK12 is altered in 0.94% of non-hodgkin lymphoma patients [4].

CDK12 Loss is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain CDK12 Loss and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

CDK12 Loss is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 Loss and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

CDK12 is altered in 1.72% of squamous cell lung carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDK12 Loss and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [5].

CDK12 is altered in 4.19% of malignant ovarian epithelial tumor patients with CDK12 Loss present in 0.14% of all malignant ovarian epithelial tumor patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CDK12 is altered in 0.85% of sarcoma patients with CDK12 Loss present in 0.08% of all sarcoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 Loss and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDK12 is altered in 4.64% of malignant uterine neoplasm patients with CDK12 Loss present in 0.03% of all malignant uterine neoplasm patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 1.94% of ampulla of vater carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CDK12 is altered in 2.52% of anal carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 Loss and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

CDK12 is altered in 0.92% of anaplastic astrocytoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDK12 is altered in 0.71% of B-cell non-hodgkin lymphoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 2.23% of bile duct adenocarcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CDK12 is altered in 2.23% of bile duct carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 3.05% of biliary tract carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 Loss is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 2.23% of cholangiocarcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 4.36% of colorectal adenocarcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CDK12 is altered in 1.18% of diffuse large B-cell lymphoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 is altered in 3.39% of esophageal squamous cell carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 0.68% of Ewing sarcoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 is altered in 5.98% of gallbladder carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 1.39% of glioblastoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 Loss and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDK12 is altered in 1.35% of glioma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 is altered in 3.64% of high grade fallopian tube serous adenocarcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 is altered in 1.16% of leiomyosarcoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 1.74% of low grade ovarian serous adenocarcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 is altered in 2.4% of lung carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 0.89% of lymphoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 Loss and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDK12 is altered in 1.33% of malignant central nervous system neoplasm patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 is altered in 7.53% of malignant esophagogastric neoplasm patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CDK12 is altered in 5.48% of malignant gastric neoplasm patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CDK12 is altered in 4.34% of malignant intestinal neoplasm patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CDK12 is altered in 0.32% of malignant mesothelioma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 4.46% of malignant small intestinal neoplasm patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

CDK12 is altered in 0.56% of mantle cell lymphoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 is altered in 1.81% of mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 Loss is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 is altered in 0.98% of multiple myeloma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 3.61% of neuroblastoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 Loss is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 is altered in 3.03% of pancreatic ductal adenocarcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 Loss and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK12 is altered in 4.55% of penile carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 Loss and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

CDK12 Loss is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 is altered in 6.25% of prostate small cell carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for prostate small cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and prostate small cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 is altered in 0.7% of renal cell carcinoma patients [4].

CDK12 Loss is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK12 Loss is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 Loss and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK12 Loss is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 Loss and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

CDK12 Loss is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 Loss and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].